Eli Lilly and Company (NYSE:LLY) Shares Sold by NN Investment Partners Holdings N.V.


Share on StockTwits

NN Investment Partners Holdings N.V. lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 43.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 253,740 shares of the company’s stock after selling 191,763 shares during the period. NN Investment Partners Holdings N.V.’s holdings in Eli Lilly and were worth $47,402,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in LLY. Perennial Advisors LLC purchased a new position in shares of Eli Lilly and in the fourth quarter valued at $31,000. Retirement Group LLC purchased a new position in shares of Eli Lilly and in the fourth quarter valued at $33,000. DB Wealth Management Group LLC purchased a new position in shares of Eli Lilly and in the fourth quarter valued at $34,000. Accel Wealth Management purchased a new position in shares of Eli Lilly and in the fourth quarter valued at $37,000. Finally, Archer Investment Corp boosted its stake in Eli Lilly and by 83.3% during the 4th quarter. Archer Investment Corp now owns 220 shares of the company’s stock valued at $37,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 75.59% of the company’s stock.

In other Eli Lilly and news, Director Jackson P. Tai bought 1,366 shares of Eli Lilly and stock in a transaction on Friday, April 30th. The stock was purchased at an average cost of $182.84 per share, for a total transaction of $249,759.44. Following the completion of the purchase, the director now directly owns 60,649 shares of the company’s stock, valued at $11,089,063.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 3,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, April 28th. The shares were sold at an average price of $181.38, for a total transaction of $544,140.00. Following the completion of the sale, the chief accounting officer now owns 5,987 shares of the company’s stock, valued at $1,085,922.06. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

A number of research firms have commented on LLY. Mizuho reduced their price objective on shares of Eli Lilly and from $228.00 to $216.00 and set a “buy” rating on the stock in a research note on Tuesday. Truist increased their price objective on shares of Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Cowen increased their price objective on shares of Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a research note on Friday, February 12th. Barclays reduced their price objective on shares of Eli Lilly and from $232.00 to $227.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Truist Securities raised their price target on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, March 22nd. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $200.75.

Shares of LLY stock traded up $2.07 during trading hours on Tuesday, reaching $187.99. The stock had a trading volume of 54,848 shares, compared to its average volume of 4,094,015. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. Eli Lilly and Company has a twelve month low of $129.21 and a twelve month high of $218.00. The firm has a 50-day simple moving average of $185.84 and a 200-day simple moving average of $176.06. The firm has a market capitalization of $180.28 billion, a PE ratio of 30.38, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Monday, April 26th. The company reported $1.87 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.12 by ($0.25). Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The firm had revenue of $6.81 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same period last year, the business earned $1.75 EPS. The firm’s revenue was up 16.1% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 7.56 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 10th. Shareholders of record on Friday, May 14th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 1.81%. Eli Lilly and’s payout ratio is 56.29%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Article: Margin

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.